Fig. 1.
T-cell growth curves of 27 autologous CD4ζ-modified CD4+ and CD8+ T-cell products in 25 enrolled subjects.
The minimum starting cell count was 5 × 109. Transduction with CD4ζ retroviral supernatant occurred on days 5 and 7, followed by expansion in serum-free medium containing IL-2 (200 IU/mL) and antiretroviral agents until reaching the target cell dose of 3 × 1010 cells (horizontal line on chart). Cell processing was successful in 24 of 25 subjects (the 2 failed cultures are depicted with the dashed lines). Both patients underwent repeat lymphapheresis, and 1 was successfully processed the second time.
